Physician profile
Johnny Jones
NPI 1235397308
$10,383.07
in general payments reported to CMS, 2019-2025
31 companies · $2,523 in 2025
The $2,523 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $641 · 2021: $1,416 · 2022: $1,613 · 2023: $1,577 · 2024: $1,844 · 2025: $2,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,079 · Travel and Lodging: $751 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,079.09 |
| Travel and Lodging | $751.13 |
| Education | $113.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,104.22 | 2019-2025 | |
| Medtronic, INC. | $962.90 | 2025 | Interstim |
| Janssen Biotech, INC. | $716.19 | 2019-2025 | Stelara, Tremfya, Remicade |
| Gilead Sciences, INC. | $445.42 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $411.41 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $331.32 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $311.78 | 2019-2023 | Trulance |
| Braintree Laboratories, INC. | $261.25 | 2019 | |
| Genzyme Corporation | $189.75 | 2022-2025 | |
| Pfizer INC. | $173.46 | 2019-2025 | |
| Lilly USA, LLC | $149.98 | 2023-2025 | Omvoh, Zepbound |
| Aimmune Therapeutics, INC. | $136.73 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $134.71 | 2020-2023 | |
| Ardelyx, INC. | $133.18 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $130.92 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $107.05 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $104.56 | 2021-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $92.97 | 2024-2025 | Iqirvo |
| Celgene Corporation | $83.18 | 2022-2023 | Zeposia |
| Amgen INC. | $76.62 | 2020-2024 | Uplizna |
| Celltrion USA INC. | $71.70 | 2024-2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $57.65 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $43.72 | 2019-2020 | |
| Qol Medical, LLC | $30.65 | 2022-2023 | Sucraid |
| Madrigal Pharmaceuticals | $24.02 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $22.50 | 2019 | |
| Intercept Pharmaceuticals, INC. | $17.87 | 2019 | |
| Allergan, INC. | $16.33 | 2019 | |
| Enterra Medical, INC. | $15.63 | 2023 | |
| Boston Scientific Corporation | $13.83 | 2020 | |
| Alfasigma USA, INC. | $11.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.